Oncimmune's range of diagnostic tests profile the body’s immune response to detect evidence of the body’s natural response to cancer, which can detect cancer on average four years earlier than standard clinical diagnosis.
The City broker's forecasts are unchanged, while it has reiterated its 150p share price target
Small caps
Oncimmune Holdings' collaborate with US based Augmenta Bioworks to profile patient plasma samples
Small caps
Oncimmune Holdings' reports 'a year of opportunities' with EarlyCDT lung screening technology
